» Articles » PMID: 36557068

Oxidative Stress and Inflammatory Biomarkers in Patients with Diabetic Foot

Abstract

Background and Objectives: Diabetic foot (DF) development is driven by complex interactions of hyperglycemia, inflammation, and oxidative stress (OS). We aimed to investigate OS and inflammatory biomarkers in patients with DF and their potential to improve early diagnosis and management of DF. Materials and Methods: The prooxidant−antioxidant balance (PAB), superoxide dismutase (SOD), total oxidative status (TOS), total sulfhydryl groups (SHG), routine biochemical parameters, and complete blood count were determined in 42 patients with type-2 DM, of which 23 patients had DF, while 19 patients were without DF complications. The neutrophils-to-lymphocyte ratio (NLR) was evaluated as a biomarker of inflammation. Results: Patients with DF had significantly higher (p < 0.05) PAB levels (170 ± 33.9 U/L) compared to those without DF complications (142 ± 31.3 U/L). In addition, patients with DF had significantly reduced SOD activities (p < 0.01). NLR values were significantly higher in the DF group (median: 2.8; interquartile range: 2.0−4.3) than in the group without DF (median: 1.4; interquartile range: 1.4−2.1; p < 0.01). A positive correlation was found between the PAB and NLR index (r = 0.449; p < 0.05). The diagnostic accuracy of both PAB (AUC = 0.741; p < 0.01) and NLR (AUC = 0.760; p < 0.01) was estimated as acceptable. Conclusions: In conclusion, the development of DF is associated with enhanced OS and inflammation processes. PAB and NLR could be useful non-invasive biomarkers of DF development.

Citing Articles

The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives-A Narrative Review.

Miceli G, Basso M, Pennacchio A, Cocciola E, Pintus C, Cuffaro M Medicina (Kaunas). 2024; 60(11).

PMID: 39596981 PMC: 11596194. DOI: 10.3390/medicina60111796.


Update on Biomarkers of Chronic Inflammatory Processes Underlying Diabetic Neuropathy.

Stoian A, Muntean C, Baba D, Manea A, Denes L, Simon-Szabo Z Int J Mol Sci. 2024; 25(19).

PMID: 39408723 PMC: 11476795. DOI: 10.3390/ijms251910395.


Advanced multifunctional hydrogels for diabetic foot ulcer healing: Active substances and biological functions.

Li Y, Leng Y, Liu Y, Zhong J, Li J, Zhang S J Diabetes. 2024; 16(4):e13537.

PMID: 38599855 PMC: 11006623. DOI: 10.1111/1753-0407.13537.


Negative pressure wound therapy promotes wound healing of diabetic foot ulcers by up-regulating PRDX2 in wound margin tissue.

Tang Y, Liu L, Jie R, Tang Y, Zhao X, Xu M Sci Rep. 2023; 13(1):16192.

PMID: 37758743 PMC: 10533814. DOI: 10.1038/s41598-023-42634-9.


Endogenous Biological Drivers in Diabetic Lower Limb Wounds Recurrence: Hypothetical Reflections.

Berlanga-Acosta J, Garcia-Ojalvo A, Guillen-Nieto G, Ayala-Avila M Int J Mol Sci. 2023; 24(12).

PMID: 37373317 PMC: 10299311. DOI: 10.3390/ijms241210170.

References
1.
Vekic J, Zeljkovic A, Al Rasadi K, Cesur M, Silva-Nunes J, Pantea Stoian A . A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies. Metabolites. 2022; 12(2). PMC: 8879153. DOI: 10.3390/metabo12020108. View

2.
Rizvi A, Kathuria A, Al Mahmeed W, Al-Rasadi K, Al-Alawi K, Banach M . Post-COVID syndrome, inflammation, and diabetes. J Diabetes Complications. 2022; 36(11):108336. PMC: 9534783. DOI: 10.1016/j.jdiacomp.2022.108336. View

3.
Bolajoko E, Mossanda K, Adeniyi F, Akinosun O, Fasanmade A, Moropane M . Antioxidant and oxidative stress status in type 2 diabetes and diabetic foot ulcer. S Afr Med J. 2008; 98(8):614-7. View

4.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157:107843. DOI: 10.1016/j.diabres.2019.107843. View

5.
Maiese K, Morhan S, Chong Z . Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res. 2007; 4(1):63-71. PMC: 2387116. DOI: 10.2174/156720207779940653. View